Healthcare venture investing has always been a competition to identify the best companies. This next decade will belong to the investors identifying the best breakthroughs before they become companies at all. And that distinction matters.
Most healthcare investors are familiar with the traditional venture playbook: wait for something to emerge, evaluate the market opportunity, assess clinical and regulatory progress, and invest once enough risk has been removed to justify the valuation.
That model can produce exceptional companies and returns. But, the landscape is changing. Increasingly, the most valuable opportunities are originating inside academic medical centers, research institutions, and hospitals long before they resemble venture-backed startups. By the time many investors approach them, a significant portion of the value creation has already occurred.
The question is no longer whether healthcare innovation is accelerating. The question is where investors gain access to generate the strongest returns.
The migration of innovation
Many of healthcare’s most important breakthroughs still begin in the same place they always have: university laboratories, clinical research programs, and academic medical centers. What has changed is the speed at which these discoveries can move toward commercialization.
Artificial intelligence is accelerating drug discovery, diagnostics, clinical decision support, and healthcare operations. Advances in genomics, computational biology, and precision medicine continue to create entirely new categories of companies. Researchers who once required years of infrastructure and capital to validate ideas can now reach meaningful milestones far more quickly.
And, as a result, the distance between scientific discovery and company formation is shrinking.
However, many venture firms review companies before an academic founder has developed a commercialization and growth plan. They are optimized to assess a business , not emerging research or scientific discoveries that have not yet entered the venture ecosystem — creating a growing disconnect between where innovation originates and where capital is most often deployed.
The real scarcity is access
Healthcare investors rarely suffer from a shortage of opportunities. They suffer from a shortage of differentiated access and the skills to identify what to support.
By Series A, the strongest healthcare companies often attract dozens of investors. Founders have multiple options, information is widely available, and competition drives valuations higher.
The challenge is not identifying promising companies. It is understanding how to move the innovation from the lab into commercialization. This is where academic ecosystems can create a meaningful advantage.
Researchers, physicians, and clinician-scientists are often building technologies years before they appear on a traditional venture firm’s radar. Many discoveries remain hidden within institutions because they have not yet secured commercialization support, assembled management teams, or developed venture-ready narratives.
The result: one of the last areas of healthcare investing where information asymmetry still meaningfully exists.
Why traditional signals are becoming less useful
Many venture investors rely on familiar milestones to reduce uncertainty: clinical validation, regulatory progress, customer adoption, revenue traction, and financing history. These indicators remain important. The problem is that they are increasingly visible to everyone.
As capital has become more abundant and healthcare venture markets more competitive, traditional signals have become less differentiated. By the time a company demonstrates strong traction, much of the market has already recognized the opportunity.
The best opportunities are often identified before these signals appear — requiring different variables to be evaluated. The quality of the underlying science, the strength of intellectual property, founder potential, clinical relevance, and the probability that a discovery can become a scalable business are all crucial factors these days.
The institutional blind spot
Many institutional investors acknowledge the importance of early innovation but struggle to participate effectively. The challenge is structural.
Evaluating emerging science requires domain expertise that extends beyond traditional venture diligence. Sourcing opportunities requires deep relationships within universities, hospitals, and research institutions. Supporting founders often involves helping build companies from the ground up rather than simply funding existing businesses.
These capabilities are difficult to replicate. As a result, a significant portion of healthcare innovation remains undercapitalized during the phase when valuation is lowest and investor competition is limited.
For investors capable of operating in these environments, that inefficiency creates opportunity.
Looking ahead
Healthcare venture capital has always rewarded investors who identify important trends before consensus forms. Today, one of the most important shifts is happening at the earliest stage of company creation.
The next generation of transformative healthcare companies will not emerge from startup ecosystems alone. For healthcare investors, the opportunity is not simply finding the next great company. It is building access to the environments and providing support where those companies are born.
That is increasingly where the next source of alpha resides.
Getty Images: John Lund
Derek Minno is a veteran venture capital investor, entrepreneur, and author with more than 40 years of experience in private markets and venture investing. As President of Point Capital, he has managed portfolios exceeding $6 billion and invested in venture funds and companies across the U.S. and internationally. A Chartered Financial Analyst (CFA) with an MBA from Carnegie Mellon University, Derek has held leadership roles at Mellon Bank, Point Venture Partners, and Wilshire Private Markets. Throughout his career, he has invested alongside top firms including Sequoia Capital, Kleiner Perkins, HarbourVest, and New Enterprise Associates (NEA), with portfolio exposure to companies such as Facebook and Tesla. Drawing on experience as an investor, entrepreneur, and fund manager, Derek is recognized for his expertise in venture capital and venture secondary investing.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
